J&J CEO Gorsky Handing Over Reins To Vice Chairman Duato
Gorsky Will Transition To Executive Chairman
Joaquin Duato has been involved for the last several years in growing J&J’s pharma and consumer businesses and has led the company’s COVID-19 efforts. Alex Gorsky is stepping down due to a family health issue.
You may also be interested in...
Johnson & Johnson’s medical device sales were up nearly 60% year-over-year in the second quarter of 2021 while Abbott reported 51% growth in its device business, reflecting the recovery in procedure volumes since the worst days of the pandemic in mid-2020.
NY AG has ‘no comment’ on whether criminal charges will be pursued against company executives; NC AG predicts ‘north of 40 states’ expected to accept settlement and would then need to convince municipalities to come on board. States with ongoing litigation against manufacturers may opt for jury trial instead.
In first of what could be similar April-June earnings results from major consumer health firms, J&J reports 9.2% operational growth to $3.74bn in sales. Worldwide consumer health chief Thibaut Mongon touts segment’s results and outlook but says similar growth in second half isn’t assured.